Seeking Alpha
 

Stryker Corporation (SYK)

- NYSE
  • Thu, Jul. 23, 4:33 PM
    • Stryker (NYSE:SYK): Q2 EPS of $1.20 beats by $0.03.
    • Revenue of $2.43B (+3.0% Y/Y) in-line.
    • Press Release
    | Comment!
  • Thu, Jul. 23, 4:18 PM
    • Stryker (NYSE:SYK) Q2 results ($M): Total Revenues: 2,432 (+2.9%); Orthopedics: 1,035 (+0.7%); Medsurg: 939 (-8.7%); Neurotech & Spine: 458 (+6.5%).
    • Net Income: 392 (+82.3%); EPS: 1.03 (+83.9%); CF Ops: 357 (-2.5%).
    • 2015 Guidance: Organic sales growth: 5.5 - 6.5%; Non-GAAP EPS: $5.06 - 5.12 from $4.95 - 5.10. If forex holds at present levels, EPS will be negatively impacted ~$0.25.
    • Q3 Guidance: Non-GAAP EPS: $1.20 - 1.25.
    | Comment!
  • Wed, Jul. 22, 12:52 PM
    • Stryker (SYK -0.6%) reports tomorrow after the close. Consensus view is EPS of $1.17 (+109%) on revenues of $2.4B (+2%).
    | Comment!
  • Tue, Apr. 21, 6:16 PM
    • Stryker (NYSE:SYK) Q1 results ($M): Total Revenues: 2,379 (+3.2%); Net Income: 224 (+220.0%); GAAP EPS: 0.58 (+222.2%); CF Ops: 380 (+84.5%); Quick Assets: 4,263 (+5.3%).
    • Sales by segment: Orthopedics: 1,023 (+2.4%), Knees: 345 (-0.9%), Hips: 312 (-1.9%), Trauma & Extremities: 313 (+8.7%); Medsurg: 927 (+4.6%), Instruments: 346 (+0.9%), Endoscopy: 321 (+2.9%), Medical: 205 (+13.3%); Neurotech & Spine: 429 (+2.1%), Neurotechnology: 252 (+3.7%), Spine: 177 (0.0%).
    • Medsurg sales growth has decelerated the past three quarters: 23.6%, 16.3%, 12.1%, 4.6%.
    • Q2 Guidance: Non-GAAP EPS: $1.15 - 1.20.
    • 2015 Guidance: Organic sales growth: 5 - 6%; Non-GAAP EPS: $4.95 - 5.10 from $4.90 - 5.00.
    • If foreign currency exchange rates remain unchanged, sales in Q2 and 2015 will be negatively impacted by 3.5 - 4.5% and non-GAAP EPS by $0.25 - 0.30, half of which will be in H1.
    | Comment!
  • Tue, Apr. 21, 4:49 PM
    • Stryker (NYSE:SYK): Q1 EPS of $1.11 beats by $0.03.
    • Revenue of $2.38B (+3.5% Y/Y) in-line.
    • Press Release
    | Comment!
  • Tue, Apr. 21, 1:34 PM
    • Stryker (SYK +1.3%) will report Q1 results after today's close. Consensus view is EPS of $1.08 on revenues of $2.4B.
    | Comment!
  • Mon, Apr. 20, 5:35 PM
  • Tue, Jan. 27, 4:54 PM
    • Stryker (NYSE:SYK): Q4 EPS of $1.44 misses by $0.01.
    • Revenue of $2.62B (+6.1% Y/Y) in-line.
    • Press Release
    | Comment!
  • Tue, Jan. 27, 4:23 PM
    • Stryker (NYSE:SYK) Q4 results ($M): Revenues: 2,618 (+6.1%), U.S.: 1,818 (+11.1%), Intl: 800 (-3.8%); COGS: 892 (+4.7%); R&D Expense: 153 (+10.1%); SG&A Expense: 1,059 (+4.7%); Net Income: 260 (-32.6%); EPS: 0.67 (-33.7%); CF Ops: 675 (+0.4%); Quick Assets: 5,000 (+25.6%).
    • Gross Profit: 1,726 (+6.8%); COGS: 34.1% (-1.3%); Gross Margin: 65.9% (+0.7%); Operating Earnings: 514 (+10.3%); Operating Earnings Yield: 19.6% (+4.0%); Net Earnings Yield: 9.9% (-36.5%).
    • Sales by segment: Orthopedics: 1,110 (+1.7%), Knees: 363 (-2.2%), Hips: 331 (-2.9%), Trauma & Extremities: 335 (+9.1%); Medsurg: 1,054 (+12.1%), Instruments: 393 (+12.3%), Endoscopy: 390 (+10.8%), Medical: 218 (+16.0%); Neurotech & Spine: 454 (+3.9%), Neurotechnology: 262 (+9.2%), Spine: 192 (-2.5%).
    • Q1 Guidance: Non-GAAP EPS: $1.05 - 1.10.
    • 2015 Guidance: Organic sales growth: 4.5 - 6.0%; Non-GAAP EPS: $4.90 - 5.00.
    | Comment!
  • Mon, Jan. 26, 5:35 PM
  • Tue, Jan. 13, 6:57 PM
    • Stryker (NYSE:SYK) expects to report Q4 EPS of $1.43-$1.45, below a $1.46 consensus. Net sales growth rose 6.1% (8.6% at constant currency) to $2.6B, below a $2.63B consensus.
    • Orthopaedics sales rose 1.7%, MedSurg 12.1%, and Neurotechnology & Spine 3.9%. Organic sales growth was 5.5%. U.S. sales +11.1% to $1.8B; international -3.8% to $800M (+3.8% in constant currency).
    • The medical device maker also says it now expects forex to have a $0.20 impact on 2015 EPS, worse than prior guidance of $0.10-$0.12.
    • SYK -1.3% AH. Full Q4 results arrive after the close on Jan. 27.
    | Comment!
  • Oct. 16, 2014, 4:35 PM
    • Stryker (NYSE:SYK): Q3 EPS of $1.15 beats by $0.01.
    • Revenue of $2.39B (+11.2% Y/Y) beats by $70M.
    • Shares +.32%.
    • Press Release
    | Comment!
  • Oct. 16, 2014, 4:15 PM
    • Stryker (SYK -0.4%) Q3 results ($M): Total Revenues: 2,389 (+11.1%); Gross Profit: 1,567 (+6.7%); Operating Expenses: 1,063 (-16.4%); Operating Income: 450 (+300.0%); Net Income: 57 (-44.7%); EPS: 0.16 (-40.7%); Quick Assets: 4,677 (+17.5%); CF Ops: 535 (-14.0%).
    • Revenue by geography: U.S.: 1,628 (+12.4%); International: 761 (+8.4%).
    • Revenue by business: Reconstructive: 1,016 (+8.5%); MedSurg: 936 (+16.3%); Neurotech and Spine: 437 (+6.7%).
    • 2014 Guidance: Organic sales growth: 5 - 6% (unch); non-GAAP EPS: at the low end of $4.75 - 4.80.
    | Comment!
  • Oct. 16, 2014, 10:52 AM
    • Stryker (SYK -0.1%) reports Q3 results today after the close. The conference call will begin at 4:30 pm ET.
    • Consensus view is EPS of $1.14 on revenues of $2.32B.
    | Comment!
  • Oct. 15, 2014, 5:35 PM
  • Jul. 17, 2014, 4:28 PM
    • Stryker (SYK -0.7%) Q2 results: Net Sales: $2,363M (+6.8%); COGS: $808M (+10.7%); R&D Expense: $158M (+19.7%); SG&A Expense: $1,038M (+2.3%); Operating Income: $307M (+5.9%): Net Income: $215M (+0.9%); EPS: $0.56 (unch); Quick Assets: $4,745M (+19.2%); CF Ops: $366M (+2.8%).
    • 2014 Guidance: Organic sales growth: 5.0 - 6.0%; adjusted diluted EPS: $4.75 - 4.80.
    | Comment!
Visit Seeking Alpha's
SYK vs. ETF Alternatives
Company Description
Stryker Corporation is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products.